The Global Tissue Engineering Market is estimated to be valued at US$ 9,436.0 million in 2022 and is expected to exhibit a CAGR of 11.7% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.

 

Tissue engineering involves the development of functional organs and tissues to replace damaged or diseased tissues through the combination of cells, biomaterials, and engineering techniques. The market offers several products such as scaffolds, tissue grafts, and biomaterials, which find application in wound care, orthopedics, cardiovascular diseases, and neurology, among others. These technologies enable the regeneration and restoration of damaged tissues, providing improved and personalized treatment options for patients.

The global tissue engineering market is expected to witness high growth, exhibiting a CAGR of 11.7% over the forecast period (2022-2030), due to increasing demand for organ transplantation and advancements in regenerative medicine. In terms of regional analysis, North America is projected to be the fastest-growing and dominating region due to the presence of key market players, strong healthcare infrastructure, and supportive government initiatives. Major key players operating in the tissue engineering market include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet. These companies are involved in continuous research and development activities, strategic collaborations, and product innovations to strengthen their market position.

Read More:

https://healthideologist.blogspot.com/2023/10/tissue-engineering-market-to-reach-us.html